ARCHIVED: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. Axi-cel was approved by the U.S. Food and Drug Administration for treatment of DLBCL in October 2017 and by the European Commission in August 2018.
The study, co-led...
ARCHIVED: MD Anderson, Houston Dynamo team up for one goal: end cancer
Â鶹ӳ» MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end cancer...
ARCHIVED: Peers choose MD Anderson¡¯s Gershenwald, Hwu as new AAAS Fellows
Two leaders in the field of melanoma treatment ¨C a surgeon and an oncologist ¨C from Â鶹ӳ» MD Anderson Cancer Center have...
ARCHIVED: Stand Up to Cancer funds innovative approach to pancreatic cancer
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer.
The project led by researchers from Â鶹ӳ» MD Anderson Cancer Center and Baylor College of Medicine will collect T cells ¨C the immune system¡¯s targeted warriors?¨C from tumors, expand their...
ARCHIVED: FDA restrictions on e-cigarettes an important step to protect the health of youth
Â鶹ӳ» MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies
A Phase I/II study, led by investigators at Â鶹ӳ» MD Anderson Cancer Center, reports an investigational drug called tagraxofusp...
ARCHIVED: Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called...
ARCHIVED: First UT System clinical collaboration launches between MD Anderson, UTMB Health
Â鶹ӳ» MD Anderson Cancer Center today formally opened a four-story facility in League City that houses new and expanded...
ARCHIVED: Fecal transplant effective against immunotherapy-induced colitis
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
ARCHIVED: Combination chemotherapy and immunotherapy effective in Phase II leukemia study
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...